RABL6 has been reported to promote proliferation of osteosarcoma and pancreatic neuroendocrine tumor through inhibition of retinoblastoma 1 (pRb) (Tang et al., 2016; Hagen et al., 2014). Here, RB1 is linked to pancreatic neuroendocrine tumor.